<bill session="117" type="s" number="4378" updated="2022-12-29T17:33:52Z">
  <state datetime="2022-06-13">REFERRED</state>
  <status>
    <introduced datetime="2022-06-13"/>
  </status>
  <introduced datetime="2022-06-13"/>
  <titles>
    <title type="display">Hatch-Waxman Improvement Act of 2022</title>
    <title type="short" as="introduced">Hatch-Waxman Improvement Act of 2022</title>
    <title type="official" as="introduced">A bill to reauthorize a provision of the Federal Food, Drug, and Cosmetic Act pertaining to drugs containing single enantiomers.</title>
  </titles>
  <sponsor bioguide_id="M001198"/>
  <cosponsors/>
  <actions>
    <action datetime="2022-06-13">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-06-13" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="4348" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-10-18T15:02:37Z" status="Introduced in Senate">Hatch-Waxman Improvement Act of 2022

This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of one another).</summary>
</bill>
